Anavex Life Sciences Corp (AVXL)

[falconer66a]

Missling Machinations, for Ultimate Anavex Benefit

So MOA works, but why does it take so very long to present data results when many here feel it's just a few weeks to maybe several months?

Of course, this is the big question, for everyone examining Anavex.

If the mechanism of action, the ability of blarcamesine to effectively restore cellular processes to normality (disease obviation) actually happens, what's the holdup in seeing human clinical results that show this?

Well, I don't know. Like everyone else I've been waiting for the segregated, full release of the clinical outcomes of the Alzheimer's patients who were dosed at the 50mg level. I suspect that Missling is sitting in on any number of conversations and inquiries from prospective corporate suitors who are trying to arrange collaborations or contracts involving blarcamesine. He therefore has intelligently elected to keep a great deal of information closely held. He's trying to arrange the very best new collaborations. Those aren't discussions or have information that should be floating around on public message boards.

If none of this works, I'm out a few thousands of dollars. But Missling will be out many millions. His imperatives to get things right and end up with regulatory approval of blarcamesine are immense. Self-interest will drive things toward a favorable conclusion. It's just taking a lot longer than most have hoped.

And it's not just one set of clinical results that will factor into Anavex success. What if the Alzheimer's data are muddy and indistinct and don't seem they will be able to induce FDA approval? There's the Rett results. Very high chance that when fully analyzed and released blarcamesine will gain approval. Followed by Parkinson's disease dementia.

With sound, incontrovertible data from any one of these clinical trials, Anavex will become a revenue-generating pharmaceutical. But a matter of time. Those who can't or won't wait shouldn't have an AVXL position. Wait for FDA approval.